Ironwood Pharmaceuticals (IRWD) Other Non-Current Assets (2010 - 2026)
Ironwood Pharmaceuticals (IRWD) posted Other Non-Current Assets of $4.1 million for Q1 2026, down 8.11% sequentially from $4.5 million in Q4 2025, and down 25.3% YoY from $5.5 million in Q1 2025.
Ironwood Pharmaceuticals (IRWD) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Ironwood Pharmaceuticals has reported Other Non-Current Assets for 17 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 25.3% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 25.3% YoY) and the FY2025 annual result came in at $4.5 million, down 23.99% from the prior year.
- Other Non-Current Assets declined to $4.1 million in Q1 2026 per IRWD's latest filing, from $4.5 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $6.3 million in Q3 2024 and troughed at $485000.0 in Q2 2022.
- A 5-year average of $3.3 million and a median of $3.8 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets slumped 51.5% in 2022, then soared 734.71% in 2024.
- Over 5 years, Other Non-Current Assets stood at $485000.0 in 2022, then surged by 643.92% to $3.6 million in 2023, then jumped by 64.16% to $5.9 million in 2024, then slipped by 23.99% to $4.5 million in 2025, then decreased by 8.11% to $4.1 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.1 million, $4.5 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Ironwood Pharmaceuticals | 706.94 Mn | 627.81 Mn | - | 3.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.87 Mn |
| Mar 31, 2026 | 4.14 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.84 Mn |
| Jun 30, 2025 | 5.15 Mn |
| Mar 31, 2025 | 5.54 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | 6.29 Mn |
| Jun 30, 2024 | 4.26 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 3.61 Mn |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 510,000.00 |
| Mar 31, 2023 | 820,000.00 |
| Dec 31, 2022 | 485,000.00 |
| Sep 30, 2022 | 863,000.00 |
| Jun 30, 2022 | 485,000.00 |
| Mar 31, 2022 | 955,000.00 |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 485,000.00 |